You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1336 Results
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Nov 2019
Regimen
Intent: Palliative
Aug 2020
Regimen
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
New Drug Funding Program
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
  • prednisone
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative
Funding:
ODB - General Benefit
  • prednisone
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Funding:
ODB - General Benefit
  • procarbazine
ODB - General Benefit
  • prednisone
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
Aug 2020

Pages